Jennerex is the leading company championing the use of oncolytic viruses in the treatment of cancer. Based on its early pre-clinical successes - it's been able to raise $45 M in funding from foreign companies Green Cross Korea, China's Lee Pharmaceuticals, and France's Transgene. See Xconomy.
This week Transgene announced a new $116 M deal with Jennerex to help fund its latest phase III trial - targetting solid tumors from liver and colorectal cancers. Jennerex appears to have improved the ability to delivery the therapeutic virus, JX-594, to the tumors via intravenuous injection instead of direct injection to solid tumors. This allows the treatment to also attack metastatic cancers and suppresses relapse.
Jennerex's next hurdle is to show it can improve cancer patient's survival time. The next studies with Transgene should provide that data and will allow the firm to seek FDA approval for its treatment if successful. "When this hits" says David Kim, CEO, "It will be bigger than monoclonal antibodies"
Posted by Bruce Lehr September 9th 2010.